HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer

Espiau Romera, A. ; Cuesta Guardiola, T. ; Benito Vielba, M. ; De Bonrostro Torralba, C. (Universidad de Zaragoza) ; Coronado Martín, P.J. ; Baquedano Mainar, L.

Resumen: Endometrial cancer is the most common genital cancer in high-resource countries. Treatment is essentially surgical, but the role of lymphadenectomy in the treatment of low-stage and low-grade tumors has not been defined. Although no tumor factors have been validated for use as preoperative prognostic markers of endometrial cancer at yet, human epididymis protein 4 (HE4) has received much interest as a potential diagnostic and prognostic tumor marker. Since 2008, several studies have explored its utility in the management of endometrial cancer: HE4 may be a useful preoperative prognostic marker because it is associated with lymphatic metastasis and other unfavorable factors in endometrial cancer. In addition, some studies have explored a HE4 cutoff value to classify patients according to lymph node involvement. HE4 might be beneficial as a serum marker that helps clinicians in the decision-making algorithm for treatment of endometrial cancer, enabling them to perform individualized operations and decrease the adverse effects of unnecessary surgery.

Idioma: Inglés

DOI: 10.1002/ijgo.13140

Año: 2020

Publicado en: International Journal of Gynecology and Obstetrics 149, 3 (2020), 265-268
ISSN: 0020-7292

Factor impacto JCR: 3.561 (2020)

Categ. JCR: OBSTETRICS & GYNECOLOGY rank: 20 / 83 = 0.241 (2020) - Q1 - T1

Factor impacto SCIMAGO: 0.895 - Obstetrics and Gynecology (Q2) - Medicine (miscellaneous) (Q2)

Tipo y forma: Revisión (PostPrint)

Área (Departamento): Área Obstetricia y Ginecología (Dpto. Cirugía)